13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
29 檔
20.6%
In Q4 2025, Great Point Partners LLC's U.S. equity holdings reached a combined market value of $529.1M, distributed across 29 disclosed stock positions.
Great Point Partners LLC executed strategic sector rebalancing during Q4 2025, establishing 12 new positions while fully exiting 13 holdings and trimming 4 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 9.15% | -7.23% | EXIT | |
| 2 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 6.85% | -3.21% | +2.94% | |
| 3 | ✓ | Zura Bio LTD | Stock-Other | 6.48% | -1.07% | — | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 6.44% | — | — | |
| 5 | RAPT | Rapt Therapeutics Inc | Stock-Other | 6.38% | — | — | |
| 6 | IMVT | Immunovant Inc | Stock-Other | 6.18% | -3.11% | EXIT | |
| 7 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.00% | — | +77.78% | |
| 8 | VOR | Vor Biopharma Inc | Stock-Other | 5.81% | -1.27% | — | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.68% | — | +31.68% | |
| 10 | JBIO | Jade Biosciences Inc | Stock-Other | 4.03% | -3.11% | EXIT | |
| 11 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.59% | -3.12% | EXIT | |
| 12 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.96% | +0.45% | — | |
| 13 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 2.94% | -0.50% | — | |
| 14 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.93% | — | — | |
| 15 | NKTR | Nektar Therapeutics | Stock-Other | 2.89% | -2.92% | -29.76% | |
| 16 | UPB | Upstream Bio Inc | Stock-Other | 2.64% | — | — | |
| 17 | NGNE | Neurogene Inc | Stock-Other | 2.34% | -0.23% | -21.67% | |
| 18 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.24% | +3.79% | NEW | |
| 19 | CNTX | Context Therapeutics Inc | Stock-Other | 2.23% | -1.35% | EXIT | |
| 20 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 2.13% | +0.05% | — | |
| 21 | EVMN | Evommune Inc | Stock-Other | 1.80% | -0.90% | — | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.80% | +1.23% | — | |
| 23 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.59% | -0.31% | — | |
| 24 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 1.49% | -1.20% | EXIT | |
| 25 | CLYM | Climb Bio Inc | Stock-Other | 1.27% | +0.36% | — | |
| 26 | SANA | Sana Biotechnology Inc | Stock-Other | 0.92% | — | — | |
| 27 | PHVS | Pharvaris N.V. | Stock-Other | 0.75% | -0.54% | EXIT | |
| 28 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.73% | -0.43% | EXIT | |
| 29 | RZLT | Rezolute Inc | Stock-Other | 0.73% | +0.27% | -61.18% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | +4.2% | +23.03% | Add |
| 2 | IMVT | Immunovant Inc | +2.9% | +50.00% | Add |
| 3 | JBIO | Jade Biosciences Inc | +1.8% | +27.45% | Add |
| 4 | DNTH | Dianthus Therapeutics Inc | +0.4% | +31.68% | Add |
| 5 | CNTX | Context Therapeutics Inc | +0.4% | — | Unchanged |
| 6 | ORKA | Oruka Therapeutics Inc | +0.4% | — | Unchanged |
| 7 | UPB | Upstream Bio Inc | +0.3% | — | Unchanged |
| 8 | UNCY | Unicycive Therapeutics Inc | +0.1% | — | Unchanged |
| 9 | EPRX | Eupraxia Pharmaceuticals Inc | 0% | — | Unchanged |
| 10 | SANA | Sana Biotechnology Inc | -0.1% | — | Unchanged |
| 11 | SLNOEUR | Soleno Therapeutics Inc | -0.3% | +77.78% | Add |
| 12 | ✓ | Zura Bio LTD | -0.3% | — | Unchanged |
| 13 | NGNE | Neurogene Inc | -0.9% | -21.67% | Trim |
| 14 | PHVS | Pharvaris N.V. | -0.9% | -46.62% | Trim |
| 15 | AMLX | Amylyx Pharmaceuticals Inc | -2.7% | +2.94% | Add |
| 16 | NKTR | Nektar Therapeutics | -4.2% | -29.76% | Trim |
| 17 | RZLT | Rezolute Inc | -8.8% | -61.18% | Trim |
| 18 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 19 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 20 | VOR | Vor Biopharma Inc | — | NEW | New buy |
| 21 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 22 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 24 | CTNM | Contineum Therapeutics Inc-a | — | NEW | New buy |
| 25 | FULC | Fulcrum Therapeutics Inc | — | NEW | New buy |
| 26 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 27 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 28 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 29 | CGEM | Cullinan Therapeutics Inc | — | NEW | New buy |
| 30 | EVMN | Evommune Inc | — | NEW | New buy |
| 31 | IONS | Ionis Pharmaceuticals Inc | — | EXIT | Sold out |
| 32 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 33 | SLN | Silence Therapeutics Plc-adr | — | NEW | New buy |
| 34 | TSHA | Taysha Gene Therapies Inc | — | EXIT | Sold out |
| 35 | CLYM | Climb Bio Inc | — | NEW | New buy |
| 36 | DBVT | Dbv Technologies Sa-spon Adr | — | EXIT | Sold out |
| 37 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 38 | ABSI | Absci CORP | — | EXIT | Sold out |
| 39 | HRMY | Harmony Biosciences Holdings | — | EXIT | Sold out |
| 40 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 41 | PLRX | Pliant Therapeutics Inc | — | EXIT | Sold out |
| 42 | CAPR | Capricor Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 29 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APGE, AMLX, ZURA BIO LTD) accounted for 20.6% of total reported equity market value during Q4 2025.
Top New Position Initiated
IRON
市值: $19.9M
Top Position Liquidated / Trimmed
ASND
前期市值: $14.9M
During Q4 2025, Great Point Partners LLC's top holdings by market value included APGE (9.2%)、AMLX (6.8%)、ZURA BIO LTD (6.5%). The largest single position, APGE, represented 9.2% of total portfolio value.
In Q4 2025, Great Point Partners LLC made 35 total portfolio adjustments, initiating 12 new buys, adding to 6 positions, trimming 4 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.